NCT05768880View on ClinicalTrials.gov

Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 5, 2023

Primary Completion Date

January 15, 2028

Study Completion Date

December 31, 2043

Conditions
Diffuse Intrinsic Pontine GliomaDiffuse Midline GliomaRecurrent CNS Tumor, AdultRecurrent, CNS Tumor, ChildhoodRefractory Primary Malignant Central Nervous System Neoplasm
Interventions
BIOLOGICAL

SC-CAR4BRAIN

Courses of weekly intraventricular CNS administered SC-CAR4BRAIN infusions for 3 weeks, then 1 week off

Trial Locations (1)

98105

RECRUITING

Seattle Children's Hospital, Seattle

All Listed Sponsors
lead

Seattle Children's Hospital

OTHER